ArticleJournal of family medicine and primary care2025
Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breakthrough infections (BTI) threaten the progress of the COVID-19 vaccination program towards pandemic control. To better understand the future vaccine, knowing the BTI in the general population over a while is important. Aims and Objectives: The study aimed to compare the BTI among the general population after 1 year of completion of the primary series of Covishield and Covaxin. Materials and Methods: This hospital-based prospective study was conducted among the general population beneficiaries of a COVID-19 vaccination center. Clients aged 18 years or above who had completed second vaccine dose were enrolled using systematic random sampling and followed up for 1 year. Using a semi-structured questionnaire, participants were telephonically interviewed within 1 month, 6 months, and 12 months of the second vaccine dose. Results: Out of 1682 participants who completed the study, 958 (57.0%) and 724 (43.0%) participants received Covaxin and Covishield, respectively. Twenty-nine (3.0%) Covaxin recipients and 25 (3.5%) Covishield recipients reported BTI after 1 year of follow-up with no statistically significant difference among both groups ( Conclusion: The study suggests that regardless of the type of vaccine received, the population will be at the same risk and require similar future containment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.